<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849133</url>
  </required_header>
  <id_info>
    <org_study_id>IEO S65/500</org_study_id>
    <nct_id>NCT01849133</nct_id>
  </id_info>
  <brief_title>Randomized Trial on Intraoperative Radiotherapy Full Dose Vs External Radiotherapy</brief_title>
  <acronym>ELIOT</acronym>
  <official_title>Randomized Clinical Trial: Comparison Between Quadrantectomy Followed by External Fractionated Radiotherapy and Quadrantectomy Associated With Intraoperative Radiotherapy in Women &gt;= 48 Years of Age Affected by Early-stage Breast Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of exclusive intraoperative
      radiation therapy after conserving surgery in early-stage breast cancer compared with whole
      breast radiotherapy. The primary outcome was the rate of ipsilateral true recurrence ( any
      recurrence at or close to primary tumor bed) and new ipsilateral tumors ( any recurrence
      occurring in quadrants other than the previous one) and the recurrence free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ELIOT trial is a prospective single center randomised phase III trial which compared
      intraoperative radiotherapy with electrons to the tumor bed with conventional scheme of whole
      breast external beam radiotherapy. Patients were randomly allocated to intraoperative
      radiotherapy group or external radiotherapy group in a 1:1 ratio.

      The rationale for providing partial breast irradiation to the tumor bed lies on the patterns
      of ipsilateral breast tumor relapse reported in Literature. In fact, the majority of
      recurrences occur close to the tumor bed. Several randomized trials of breast conserving
      surgery with or without whole breast radiotherapy showed that in 75-90% of cases recurrences
      were at the site of original primary tumor. In this context, limiting irradiation to the
      tumor bed may result in a similar local control as whole breast irradiation, provided that
      patients are properly selected.

      The intraoperative treatment was delivered with a mobile miniaturized accelerator, located in
      the operating room, while for external radiotherapy a 6 MV linear accelerator was used. The
      surgical technique to perform ELIOT has been standardized in every step. The breast gland is
      prepared by separating it from the subcutaneous tissue and the underlying pectoralis muscle
      and by restoring the continuity of the surgical breach after having protected the thoracic
      wall by lead and aluminium disks to optimize the delivered dose. The linear accelerator
      delivers electrons at variable energy, ranging from 3 to 9 MeV: the proper electron energy is
      chosen according to the target thickness. Collimation is achieved by hard-docking system,
      consisting of 5 mm thick high- quality polymethyl methacrylate round applicators of 4 to 10
      -cm diameter.

      For radiation protection a primary beam stopper and mobile 1.5 cm thick lead shields are
      provided. The prescribed dose was 21 Gy at the 90% isodose. After delivery of the radiation
      dose, the applicator and the disk were removed and the gland is reconstructed again.

      In the conventional arm of the study, the external beam radiotherapy is given after the full
      recovery from the surgical excision. All patients undergo virtual simulation including a
      treatment-planning CT scan. The clinical target volume is defined to extend to 5 mm below the
      skin surface and include breast parenchyma down to the deep fascia, but not including the
      underlying muscle and rib cage. The irradiated volume should extend medially to the midline,
      laterally to the mid axillary line and inferiorly to 1-2 cm below the level of intra-mammary
      fold and superiorly to the suprasternal notch. Using BEV, the blocks are used to shield as
      much heart and lung as possible without compromising the PTV.

      Treatment is delivered by a pair of tangential fields with wedges as necessary. The
      prescribed dose to the whole-breast was 50 Gy delivered in 2 Gy fraction over 5 weeks with a
      6 -megavolt linear accelerator followed by a sequential boost of 10 Gy to the tumor bed with
      electrons. A PTV dose homogeneity of -5% + 7% as recommended by ICRU (International
      Commission on Radiation Units and Measurements) report no 50.

      Patients were followed up with at least 6-month clinical examination up to 5 years and then
      every 8 months thereafter. Annual mammogram was performed .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of local relapses</measure>
    <time_frame>5 YEARS</time_frame>
    <description>local relapse of disease and ipsilateral second primary</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1305</enrollment>
  <condition>Carcinoma Breast</condition>
  <arm_group>
    <arm_group_label>ELIOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraoperative radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXTERNAL RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>external fractionated radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external fractionated radiotherapy</intervention_name>
    <description>conventional external beam radiotherapy</description>
    <arm_group_label>EXTERNAL RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intraoperative radiotherapy</intervention_name>
    <description>Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose</description>
    <arm_group_label>ELIOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 48 and &lt; 75

          -  Clinical mammographic/ultrasound diagnosis of unicentric carcinoma, with ultrasound
             diameter ≤2.5 cm. Advisable, but not mandatory, the execution of mammoscintigraphy
             with MDP-99mTc (Methyl diphosphonate technetium-99m) : this procedure allows the bone
             staging and the mapping of eventual multi-focality/multi-centricity of the breast
             neoplasm.

          -  No previous therapy (biopsy included) for breast cancer in other Institutions.

          -  Patients with non-palpable lesions will undergo preoperative centering and
             stereotactic and/or ultrasound-guided cytology (the execution of this last procedure
             is not mandatory).

          -  Adequate information to the patient and informed consent.

        Exclusion Criteria:

          -  Ductal or lobular non-infiltrating carcinoma.

          -  Paget disease.

          -  Tumor in close proximity to the skin.

          -  Tumor in the axillary tail.

          -  Documented multi-centricity/multi-focality of the tumor.

          -  Patients who underwent excisional biopsy in other Institutions.

          -  Histology different from carcinoma.

          -  Personal anamnesis positive for malignancy (basocellular carcinoma, in situ carcinoma
             of the cervix, contralateral breast cancer free of disease after 15 years of follow-up
             excluded).

          -  General contraindications to regular follow-up or radiotherapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UMBERTO VERONESI, PROF</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Zurrida S, Ivaldi G, Tosi G, Ciocca M, Tosoni A, De Lucia F. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer. 2001 Nov;37(17):2178-83.</citation>
    <PMID>11677104</PMID>
  </reference>
  <reference>
    <citation>Gatzemeier W, Orecchia R, Gatti G, Intra M, Veronesi U. [Intraoperative radiotherapy (IORT) in treatment of breast carcinoma--a new therapeutic alternative within the scope of breast-saving therapy? Current status and future prospects. Report of experiences from the European Institute of Oncology (EIO), Mailand]. Strahlenther Onkol. 2001 Jul;177(7):330-7. German.</citation>
    <PMID>11505618</PMID>
  </reference>
  <reference>
    <citation>Intra M, Gatti G, Luini A, Galimberti V, Veronesi P, Zurrida S, Frasson A, Ciocca M, Orecchia R, Veronesi U. Surgical technique of intraoperative radiotherapy in conservative treatment of limited-stage breast cancer. Arch Surg. 2002 Jun;137(6):737-40.</citation>
    <PMID>12049547</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Gatti G, Luini A, Intra M, Orecchia R, Borgen P, Zelefsky M, McCormick B, Sacchini V. Intraoperative radiation therapy for breast cancer: technical notes. Breast J. 2003 Mar-Apr;9(2):106-12.</citation>
    <PMID>12603383</PMID>
  </reference>
  <reference>
    <citation>Ciocca M, Orecchia R, Garibaldi C, Rondi E, Luini A, Gatti G, Intra M, Veronesi P, Lazzari R, Tosi G, Veronesi U. In vivo dosimetry using radiochromic films during intraoperative electron beam radiation therapy in early-stage breast cancer. Radiother Oncol. 2003 Dec;69(3):285-9.</citation>
    <PMID>14644488</PMID>
  </reference>
  <reference>
    <citation>Orecchia R, Ciocca M, Lazzari R, Garibaldi C, Leonardi MC, Luini A, Intra M, Gatti G, Veronesi P, Petit JI, Veronesi U. Intraoperative radiation therapy with electrons (ELIOT) in early-stage breast cancer. Breast. 2003 Dec;12(6):483-90.</citation>
    <PMID>14659125</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Gatti G, Luini A, Intra M, Ciocca M, Sanchez D, Zurrida S, Navarro S, Orecchia R. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery. Arch Surg. 2003 Nov;138(11):1253-6.</citation>
    <PMID>14609877</PMID>
  </reference>
  <reference>
    <citation>Intra M, Leonardi MC, Gatti G, Vento AR, Ciocca M, Veronesi P, Bassani G, Dos Santos GR, Rodriguez J, Luini A, Orecchia R, Veronesi U. Intraoperative radiotherapy during breast conserving surgery in patients previously treated with radiotherapy for Hodgkin's disease. Tumori. 2004 Jan-Feb;90(1):13-6.</citation>
    <PMID>15143964</PMID>
  </reference>
  <reference>
    <citation>Intra M, Orecchia R, Veronesi U. Intraoperative radiotherapy: the debate continues. Lancet Oncol. 2004 Jun;5(6):340.</citation>
    <PMID>15172353</PMID>
  </reference>
  <reference>
    <citation>Orecchia R, Ciocca M, Tosi G, Franzetti S, Luini A, Gatti G, Veronesi U. Intraoperative electron beam radiotherapy (ELIOT) to the breast: a need for a quality assurance programme. Breast. 2005 Dec;14(6):541-6. Epub 2005 Oct 19.</citation>
    <PMID>16242331</PMID>
  </reference>
  <reference>
    <citation>Intra M, Leonardi C, Luini A, Veronesi P, Gennari R, Gatti G, Ciocca M, Soteldo J, Bassi F, Venturino M, Orecchia R, Veronesi U. Full-dose intraoperative radiotherapy with electrons in breast surgery: broadening the indications. Arch Surg. 2005 Oct;140(10):936-9.</citation>
    <PMID>16230541</PMID>
  </reference>
  <reference>
    <citation>Luini A, Orecchia R, Gatti G, Intra M, Ciocca M, Galimberti V, Veronesi P, Santos GR, Gilardi D, Veronesi U. The pilot trial on intraoperative radiotherapy with electrons (ELIOT): update on the results. Breast Cancer Res Treat. 2005 Sep;93(1):55-9.</citation>
    <PMID>16184459</PMID>
  </reference>
  <reference>
    <citation>Orecchia R, Luini A, Veronesi P, Ciocca M, Franzetti S, Gatti G, Veronesi U. Electron intraoperative treatment in patients with early-stage breast cancer: data update. Expert Rev Anticancer Ther. 2006 Apr;6(4):605-11. Review.</citation>
    <PMID>16613547</PMID>
  </reference>
  <reference>
    <citation>Petit JY, Veronesi U, Orecchia R, Luini A, Rey P, Intra M, Didier F, Martella S, Rietjens M, Garusi C, DeLorenzi F, Gatti G, Leon ME, Casadio C. Nipple-sparing mastectomy in association with intra operative radiotherapy (ELIOT): A new type of mastectomy for breast cancer treatment. Breast Cancer Res Treat. 2006 Mar;96(1):47-51. Epub 2005 Oct 27.</citation>
    <PMID>16261402</PMID>
  </reference>
  <reference>
    <citation>Calvo FA, Meirino RM, Orecchia R. Intraoperative radiation therapy first part: rationale and techniques. Crit Rev Oncol Hematol. 2006 Aug;59(2):106-15. Epub 2006 Jul 14. Review.</citation>
    <PMID>16844383</PMID>
  </reference>
  <reference>
    <citation>Calvo FA, Meirino RM, Orecchia R. intraoperative radiation therapy part 2. Clinical results. Crit Rev Oncol Hematol. 2006 Aug;59(2):116-27. Epub 2006 Jul 21. Review.</citation>
    <PMID>16859922</PMID>
  </reference>
  <reference>
    <citation>Bernier J, Viale G, Orecchia R, Ballardini B, Richetti A, Bronz L, Franzetti-Pellanda A, Intra M, Veronesi U. Partial irradiation of the breast: Old challenges, new solutions. Breast. 2006 Aug;15(4):466-75. Epub 2006 Jan 24.</citation>
    <PMID>16439129</PMID>
  </reference>
  <reference>
    <citation>Ciocca M, Piazzi V, Lazzari R, Vavassori A, Luini A, Veronesi P, Galimberti V, Intra M, Guido A, Tosi G, Veronesi U, Orecchia R. Real-time in vivo dosimetry using micro-MOSFET detectors during intraoperative electron beam radiation therapy in early-stage breast cancer. Radiother Oncol. 2006 Feb;78(2):213-6. Epub 2005 Dec 15.</citation>
    <PMID>16359743</PMID>
  </reference>
  <reference>
    <citation>Luini A, Gatti G, Zurrida S, Talakhadze N, Brenelli F, Gilardi D, Paganelli G, Orecchia R, Cassano E, Viale G, Sangalli C, Ballardini B, dos Santos GR, Veronesi U. The evolution of the conservative approach to breast cancer. Breast. 2007 Apr;16(2):120-9. Review.</citation>
    <PMID>17403449</PMID>
  </reference>
  <reference>
    <citation>Ciocca M, Pedroli G, Orecchia R, Guido A, Cattani F, Cambria R, Veronesi U. Radiation survey around a Liac mobile electron linear accelerator for intraoperative radiation therapy. J Appl Clin Med Phys. 2009 Apr 28;10(2):2950.</citation>
    <PMID>19458597</PMID>
  </reference>
  <reference>
    <citation>Orecchia R, Ivaldi GB, Leonardi MC. Integrated breast conservation and intraoperative radiation therapy. Breast. 2009 Oct;18 Suppl 3:S98-102. doi: 10.1016/S0960-9776(09)70283-8.</citation>
    <PMID>19914553</PMID>
  </reference>
  <reference>
    <citation>Petit JY, Veronesi U, Orecchia R, Rey P, Martella S, Didier F, Viale G, Veronesi P, Luini A, Galimberti V, Bedolis R, Rietjens M, Garusi C, De Lorenzi F, Bosco R, Manconi A, Ivaldi GB, Youssef O. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat. 2009 Sep;117(2):333-8. doi: 10.1007/s10549-008-0304-y. Epub 2009 Jan 17.</citation>
    <PMID>19152026</PMID>
  </reference>
  <reference>
    <citation>Galimberti V, Ciocca M, Leonardi MC, Zanagnolo V, Paola B, Manuela S, Sahium RC, Lazzari R, Gentilini O, Peccatori F, Veronesi U, Orecchia R. Is electron beam intraoperative radiotherapy (ELIOT) safe in pregnant women with early breast cancer? In vivo dosimetry to assess fetal dose. Ann Surg Oncol. 2009 Jan;16(1):100-5. doi: 10.1245/s10434-008-0172-z. Epub 2008 Oct 21.</citation>
    <PMID>18941842</PMID>
  </reference>
  <reference>
    <citation>Rampinelli C, Bellomi M, Ivaldi GB, Intra M, Raimondi S, Meroni S, Orecchia R, Veronesi U. Assessment of pulmonary fibrosis after radiotherapy (RT) in breast conserving surgery: comparison between conventional external beam RT (EBRT) and intraoperative RT with electrons (ELIOT). Technol Cancer Res Treat. 2011 Aug;10(4):323-9.</citation>
    <PMID>21728389</PMID>
  </reference>
  <results_reference>
    <citation>Intra M, Luini A, Gatti G, Ciocca M, Gentilini OD, Viana AA, Chagas EM, Berrettini A, Schuh F, Scarpa D, Orecchia R, Veronesi U. Surgical technique of intraoperative radiation therapy with electrons (ELIOT) in breast cancer: a lesson learned by over 1000 procedures. Surgery. 2006 Sep;140(3):467-71.</citation>
    <PMID>16934611</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2013</study_first_submitted>
  <study_first_submitted_qc>May 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <last_update_submitted>May 5, 2013</last_update_submitted>
  <last_update_submitted_qc>May 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>conservative surgery</keyword>
  <keyword>intraoperative radiation therapy</keyword>
  <keyword>mobile linear accelerator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

